|
BR112019018093A2
(pt)
*
|
2017-03-30 |
2020-06-16 |
F. Hoffmann-La Roche Ag |
Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto
|
|
AU2018341781B2
(en)
*
|
2017-09-28 |
2023-03-30 |
Cstone Pharmaceuticals |
Fused ring derivative as A2A receptor inhibitor
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
KR102708681B1
(ko)
|
2018-02-13 |
2024-09-26 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
WO2019178129A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
EP4600247A3
(en)
|
2018-04-19 |
2025-11-19 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
UA126421C2
(uk)
|
2018-07-13 |
2022-09-28 |
Гіліад Сайєнсіз, Інк. |
Інгібітори pd-1/pd-l1
|
|
TW202012405A
(zh)
*
|
2018-07-24 |
2020-04-01 |
瑞士商赫孚孟拉羅股份公司 |
萘啶化合物及其用途
|
|
CN113454070A
(zh)
*
|
2018-09-30 |
2021-09-28 |
豪夫迈·罗氏有限公司 |
噌啉化合物及用于hpk1依赖性疾患诸如癌症的治疗
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
PE20211655A1
(es)
|
2018-10-31 |
2021-08-24 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
|
US20220047603A1
(en)
|
2018-12-11 |
2022-02-17 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US12492194B2
(en)
|
2019-03-26 |
2025-12-09 |
Janssen Pharmaceutica Nv |
HPK1 inhibitors
|
|
CA3129772A1
(en)
|
2019-03-26 |
2020-10-01 |
Janssen Pharmaceutica Nv |
Bicyclic hpk1 inhibitors
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
TWI848141B
(zh)
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
TW202116753A
(zh)
*
|
2019-07-11 |
2021-05-01 |
大陸商南京征祥醫藥有限公司 |
以噌啉作為hpk1的抑制劑
|
|
CN112239473B
(zh)
|
2019-07-17 |
2023-12-08 |
百济神州(北京)生物科技有限公司 |
作为hpk1抑制剂的三环化合物的制备方法
|
|
CN110483402B
(zh)
*
|
2019-08-12 |
2021-07-23 |
上海毕得医药科技股份有限公司 |
一种3-溴-5-苯基-1h-吡唑的合成方法
|
|
WO2021032148A1
(en)
*
|
2019-08-21 |
2021-02-25 |
Beigene, Ltd. |
Aminopyrazine compounds as hpk1 inhibitor and the use thereof
|
|
PH12022550605A1
(en)
*
|
2019-09-13 |
2023-09-25 |
Nimbus Saturn Inc |
Hpk1 antagonists and uses thereof
|
|
US11370803B2
(en)
|
2019-09-18 |
2022-06-28 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
PT4031547T
(pt)
|
2019-09-18 |
2024-08-27 |
Takeda Pharmaceuticals Co |
Inibidores de calicreína plasmática e utilizações dos mesmos
|
|
KR102902719B1
(ko)
|
2019-10-18 |
2025-12-24 |
포티 세븐, 엘엘씨 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
TW202140473A
(zh)
*
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
|
CN113336747A
(zh)
*
|
2020-03-03 |
2021-09-03 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
|
US12110294B2
(en)
|
2020-05-01 |
2024-10-08 |
Gilead Sciences, Inc. |
CD73 compounds
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
CN111965367A
(zh)
*
|
2020-07-23 |
2020-11-20 |
北京大学第三医院（北京大学第三临床医学院） |
Hip-55在作为gpcr偏向药物靶点中的应用
|
|
TWI908894B
(zh)
*
|
2020-09-28 |
2025-12-21 |
南韓商福斯特生物股份有限公司 |
作為造血前驅細胞激酶１（ｈｐｋ１）抑制劑的吲唑及其用途
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN114907375B
(zh)
*
|
2021-02-07 |
2026-03-31 |
苏州信诺维医药科技股份有限公司 |
杂环化合物、其制备方法、药物组合物及应用
|
|
CN114907374B
(zh)
*
|
2021-02-07 |
2026-03-10 |
苏州信诺维医药科技股份有限公司 |
杂环化合物、其制备方法、药物组合物及应用
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
CN115073308A
(zh)
*
|
2021-03-15 |
2022-09-20 |
苏州信礼发医药技术有限公司 |
1-氨甲基-1-环丙醇的合成方法
|
|
CN117396469A
(zh)
*
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的抑制剂
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2022214009A1
(zh)
*
|
2021-04-08 |
2022-10-13 |
杭州阿诺生物医药科技有限公司 |
一种高活性的hpk1激酶抑制剂
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CN117136190A
(zh)
*
|
2021-04-22 |
2023-11-28 |
浙江海正药业股份有限公司 |
芳香稠合环类衍生物及其制备方法和用途
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
AU2022376954B2
(en)
|
2021-10-29 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
AU2022419982B2
(en)
|
2021-12-22 |
2026-04-16 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023193759A1
(en)
*
|
2022-04-07 |
2023-10-12 |
Insilico Medicine Ip Limited |
Hpk1 antagonists and uses thereof
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
JP2025520511A
(ja)
*
|
2022-06-17 |
2025-07-03 |
ニューロン２３， インコーポレイテッド |
キナーゼモジュレーターおよびその使用方法
|
|
WO2024003773A1
(en)
*
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024064214A2
(en)
*
|
2022-09-21 |
2024-03-28 |
Takeda Pharmaceutical Company Limited |
Synthesis of cyclopropane carboxylic acids
|
|
CN119894905A
(zh)
*
|
2022-09-23 |
2025-04-25 |
广州威诺森医药科技有限公司 |
一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用
|
|
CN120225509A
(zh)
|
2022-12-22 |
2025-06-27 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
WO2024243025A1
(en)
*
|
2023-05-19 |
2024-11-28 |
Ikena Oncology, Inc. |
Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026089992A1
(en)
|
2024-10-21 |
2026-04-30 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|